Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?
Open Access
- 30 June 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 59 (1) , 146-152
Abstract
APL are present in between 20 and 30% of patients with SLE. They can cause vascular events (VE) or pregnancy morbidity. aCL and anti-beta-2-glycoprotein I (anti-β2GPI) are measured in clinical practice. Domain I (DI) of β2GPI is the main site for aPL binding. We investigated the prevalence of IgG anti-DI, aCL and anti-β2GPI antibodies in early SLE and their association with mortality and development of VE. Samples from 501 patients with SLE that had been obtained and stored early during their disease were tested for IgG anti-DI, aCL and anti-β2GPI antibodies by ELISA. LA status and history of VE were obtained by reviewing medical records. Kaplan–Meier analysis was used to investigate mortality and occurrence of VE, comparing groups with and without aPL in early disease. Of 501 patients, 190 (38%) had at least one of these aPL, of whom 112 had anti-DI alone. Of 276 patients with complete vascular history, 83 had experienced VE. The 39 patients who were double or triple-ELISA-positive for any combination of the three aPL were more likely to have or develop lupus anticoagulant (PP = 0.06). IgG anti-DI antibodies were present in early serum samples from 29% of patients and were more common than IgG aCL or anti-β2GPI. There was some evidence suggesting that double or triple-ELISA-positivity for these antibodies identified a group with worse outcomes.Keywords
Funding Information
- MRC (MR/P017371/1)
- Versus Arthritis Career Development Fellowship (21223)
- National Institute for Health Research University College London Hospitals Biomedical Research Centre
- Arthritis Research UK programme (19423)
This publication has 24 references indexed in Scilit:
- Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndromeThrombosis Research, 2017
- Measuring IgA Anti-β2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid SyndromePLOS ONE, 2016
- Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndromeClinica Chimica Acta, 2015
- Domain I: the hidden face of antiphospholipid syndromeLupus, 2014
- 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trendsAutoimmunity Reviews, 2014
- Evaluating the conformation of recombinant domain I of β2-glycoprotein I and its interaction with human monoclonal antibodiesMolecular Immunology, 2011
- Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid AntibodiesLupus, 2011
- Clinical course of high‐risk patients diagnosed with antiphospholipid syndromeJournal of Thrombosis and Haemostasis, 2010
- Update of the guidelines for lupus anticoagulant detectionJournal of Thrombosis and Haemostasis, 2009
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006